Paracetamol Brand Pomol-650 Among 15 Medicines Found Unsafe, Banned In Karnataka
Karnataka's food safety and drugs regulator said chemists, wholesalers, doctors, hospitals, and nursing homes should not stock, sell, or use these drugs and cosmetics
The Karnataka government on Thursday banned the use of 15 medicines, including a brand of paracetamol, after they were found unsafe by the state's food safety regulator.
Paracetamol brand Pomol-650 (paracetamol tablets IP 650 mg) and O Shanti Gold Class Kumkum manufactured in Mysuru are among the 15 medicines found unfit for use, said a circular from the state food safety and drug administration.
According to the circular, food safety and drug control under the health department had collected samples of different pharmaceutical and cosmetic products in May. Upon testing, 15 products were found unfit for use, and a warning has been issued to stakeholders.
The official statement said the chemists, wholesalers, doctors, hospitals, and nursing homes should not stock, sell, or use these drugs and cosmetics. Earlier, the state government's drug testing laboratory declared these drugs manufactured by different companies as 'substandard".
'In case they hold any stock, they are requested to inform the concerned area drugs inspector or assistant drugs controller. The public is also advised not to use these drugs or cosmetics," the statement read.
Other substandard drugs on the list include compound sodium lactate injection IP (Ringer-Lactate solution for injection) manufactured by Ultra Laboratories (batch no: KI124110) and Tam Bran Pharmaceuticals and MITO Q7 Syrup by Bion Therapeutics India (batch no: CHS-40170) among others. The department has urged strict compliance with these directions to safeguard public health.
(With PTI inputs)
First Published:
June 26, 2025, 17:02 IST
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Indian Express
2 days ago
- New Indian Express
UK trade pact does not restrict India's ability to regulate drug pricing: Govt
It said in a note that the FTA reaffirms India's right to fully use TRIPS (trade related intellectual property rights) flexibilities, including compulsory licensing and parallel imports. 'It explicitly upholds the Doha Declaration on TRIPS and Public Health, ensuring continued access to affordable medicines, says the ministry. The ministry has informed that India retains full sovereign authority to issue compulsory licences to address public health emergencies, unaffordable pricing, or unmet needs. Under compulsory licensing, the government can allow others to use patented inventions without the patent holders consent, especially when such use is related to public health. The government has clarified that the India-UK trade pact has no clause that restricts India's use of compulsory licensing in any form. 'While voluntary licensing is acknowledged under the pact as a tool for access and collaboration, it is not a precondition for compulsory licensing,' says the government. The FTA, according to the ministry, allows measures necessary to protect public health, nutrition, and national interest. 'The FTA ensures that India's right to regulate and intervene in the pharmaceutical sector for access and affordability is fully retained,' the ministry of commerce has said. It further said that India continues to be recognized globally for its public health-oriented IP regime. It says that the FTA does not impose any TRIPS-plus obligations that restrict exports of generics, nor does it change existing provisions on parallel importation, Bolar exemption, or government use of patents.
Mint
7 days ago
- Mint
India-UK FTA to boost bilateral trade for pharma, medtech, say industry bodies
The India-UK free trade agreement, signed on Thursday, is expected to open up new opportunities for Indian pharmaceutical and medical device makers. The deal is also expected to improve access to medical devices from the UK in India. Medical device manufacturers anticipate an increase in trade between the two countries but are awaiting clarity on non-tariff measures and on whether regulatory processes will be streamlined. 'Previously, medical devices imported into the UK were duty-free, so tariff restrictions were not an issue but regulatory approval costs and time were a challenge,' said Rajiv Nath, forum coordinator of industry body Association of Indian Medical Device Industry (Aimed). The body had previously sought recognition of regulatory approvals from the CDSCO or the Quality Council of India's voluntary Indian Certification for medical devices to fast-track approvals by the UK's Medicines and Healthcare products Regulatory Agency (MHRA). 'We look forward to an update on this,' said Nath. However, medtech manufacturers are also seeking strict monitoring of imports to India, to prevent other countries rerouting products into India through the UK. Mint had previously reported that domestic manufacturers raised concerns over the possibility of Chinese-origin products being routed through the UK to exploit the zero-tariff provisions under the FTA. India levies about 7.5% import duties on medical devices from the UK, which are expected to come down in a phased manner after the deal, Nath said. In 2024, medical device exports to the UK increased by 13% year-on-year to ₹ 1,015 crore, while imports from the UK rose 36% to ₹ 2,295 crore, according to Exim data. 'It not only strengthens trade ties but also opens new avenues for advanced technology collaborations between Indian and UK companies,' Himanshu Baid, managing director of Poly Medicure Ltd, said in a statement. 'With India exporting medical devices worth approximately $115 million to the UK, one of our top 10 export destinations, this agreement is poised to further boost our presence,' he added. The trade deal is also expected to open up the market for India's generic drugmakers. 'As per the indications, the pharma sector will have opportunities to supply affordable and quality assured medicine contributing to better patient care in the UK,' said Sudarshan Jain, secretary general of the Indian Pharmaceutical Alliance (IPA). 'We are awaiting further details to identify specific areas where these opportunities can be effectively leveraged,' he added. Generic players like Lupin, Biocon, Dr. Reddy's Laboratories and Wockhardt, which have exposure to the UK market, could stand to benefit.
New Indian Express
23-07-2025
- New Indian Express
All police to be trained in MAP-Drugs app as Karnataka steps up anti-narcotics drive
BENGALURU: In an effort to make Karnataka a drug-free state, all police officials and relevant department personnel across the state will undergo training on the use of the MAP-Drugs app. District-wise targets will also be set to control drug abuse and sub-committees modelled on the Anti-Narcotics Task Force (ANTF) will be established to coordinate efforts. These directions were issued during the 6th state-level Narco Coordination Committee meeting, chaired by Chief Secretary Shalini Rajneesh, at Vidhana Soudha on Tuesday. DG & IGP M A Saleem, Narcotics and Organised Crime (Cyber Command Unit) head Pronab Mohanty, Additional Chief Secretary Mohammed Mohsin and other senior officials were present. According to a press release, the chief secretary emphasised the need for police and other department officials to adopt the MAP-Drugs app and instructed that drug-related information be made available in Kannada on government websites. She also urged districts to follow the Belagavi model in tackling drug abuse. To prevent drug trafficking, Rajneesh called for intensified checks at airports and recommended including customs officials in coordination meetings. She also directed action against unregistered pharmaceutical companies and mandated that all pharmacies display boards stating: Sale without doctor's prescription is prohibited. She called for strengthening monitoring mechanisms to regulate the sale of red-listed drugs. Rajneesh also called for improved Standard Operating Procedures (SOPs) for managing de-addiction centres and directed that the public be informed about available services. Deputy commissioners were instructed to visit at least one de-addiction centre every month and submit reports. She also stressed the importance of conducting drug tests in hostels using testing kits and taking action against positive cases.
